Literature DB >> 1331352

p53 gene mutations in primary lung tumors are conserved in brain metastases.

U Schlegel1, M R Rosenfeld, M Volkenandt, M Rosenblum, J Dalmau, H Furneaux.   

Abstract

The p53 product is frequently mutated in human tumors. Both acquired and inherited mutations have been described. These mutations transform p53 from a growth suppressor gene to a transforming oncogene. We examined tissue from 6 patients with primary lung carcinoma and the corresponding brain metastases for the presence of p53 mutations by immunohistochemistry. We then confirmed and characterized the mutations by single strand conformation analysis and by direct sequence analysis. All 6 patients had primary and metastatic tumor expressing a mutant p53. The mutations were all G-T transversions and mapped to exons 5, 6, 7, and 8. The mutations in the primary tumors were precisely conserved in the brain metastases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331352     DOI: 10.1007/bf00177612

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  18 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

3.  The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen.

Authors:  E H Wang; P N Friedman; C Prives
Journal:  Cell       Date:  1989-05-05       Impact factor: 41.582

4.  Purification of DNA from formaldehyde fixed and paraffin embedded human tissue.

Authors:  S E Goelz; S R Hamilton; B Vogelstein
Journal:  Biochem Biophys Res Commun       Date:  1985-07-16       Impact factor: 3.575

5.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

6.  Wild-type p53 can inhibit oncogene-mediated focus formation.

Authors:  D Eliyahu; D Michalovitz; S Eliyahu; O Pinhasi-Kimhi; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.

Authors:  A B DeLeo; G Jay; E Appella; G C Dubois; L W Law; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

8.  Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53.

Authors:  T Soussi; C Caron de Fromentel; M Méchali; P May; M Kress
Journal:  Oncogene       Date:  1987-03       Impact factor: 9.867

9.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

Authors:  I Chiba; T Takahashi; M M Nau; D D'Amico; D T Curiel; T Mitsudomi; D L Buchhagen; D Carbone; S Piantadosi; H Koga
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  3 in total

1.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10

2.  Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics.

Authors:  M Morita; M K Rosenblum; M H Bilsky; R A Fraser; M R Rosenfeld
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

3.  Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation.

Authors:  D Matsuzoe; T Hideshima; K Ohshima; K Kawahara; T Shirakusa; A Kimura
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.